Enrico Pelz

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 76 citations

Breast Oncology, Medicine, Trastuzumab Therapy +9

Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma

Matthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos et al. · The Journal of Pathology Clinical Research · 2021 · 48 citations · Full text

Breast Oncology, Trabecular Ilc, Diagnosis +23

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

Oleg Gluz, Cornelia Kolberg‐Liedtke, Aleix Prat et al. · International Journal of Cancer · 2019 · 47 citations

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Rachel Wuerstlein, Karl Sotlar, Oleg Gluz et al. · Current Medical Research and Opinion · 2016 · 33 citations

Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid‐papillary carcinoma

Matthias Christgen, Stephan Bartels, Jana Lisa van Luttikhuizen et al. · The Journal of Pathology Clinical Research · 2017 · 33 citations · Full text